Benedetta Di Robilant
Co-founder and CSO at Dorian Therapeutics.
Benedetta di Robilant co-founded Dorian Therapeutics in 2018 where she operates as the Chief Scientific Officer.
Before founding Dorian, Benedetta joined Stanford University at the Institute for Stem Cell Biology and Regenerative Medicine (ISCBRM) as a postdoctoral fellow. She worked on self-renewal and cellular senescence in normal aging and age-related diseases, including cancer, Down syndrome and Alzheimer’s disease.
Benedetta holds a M.S. in Medical, Molecular and Cellular Biotechnology and a Ph.D. in immuno-oncology from the San Raffaele University (Milan, Italy), where she focused on adoptive immunotherapy and CAR-T cells therapies.
Benedetta is author of several scientific publications in top tier journals and she is an inventor on U.S. patents.
Visit website: https://www.doriantherapeutics.com/benedetta
See also: Dorian Therapeutics - Anti-aging company developing senoblockers.
Details last updated 25-Nov-2020